Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Clinical Lymphoma Myeloma & Leukemia

Topics

Medicine

Cancer Oncology

Internal Medicine

Genetics

Pathology And Forensic Medicine

Show all topics

DOI

10.1016/s2152-2650(24)00565-2